Published in Mol Biol Cell on December 14, 2012
Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol Suppl (2017) 0.75
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1996) 26.30
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36
The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A (1999) 10.75
The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J (1989) 10.05
Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science (1998) 8.27
Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J (1998) 6.28
Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol (1998) 6.27
PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A (1999) 4.90
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature (1987) 4.54
The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci (2008) 4.40
Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol (2000) 3.96
Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci (1998) 3.80
PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem (2001) 3.78
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29
Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem (2001) 3.27
A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci (2002) 2.62
Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J Cell Physiol (1998) 2.30
The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta (2000) 2.05
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol (2005) 1.98
Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res (2003) 1.97
Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proc Natl Acad Sci U S A (2006) 1.96
Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol (2007) 1.91
TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci (2005) 1.63
Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. FASEB J (2004) 1.61
TNF-alpha increases tyrosine phosphorylation of vascular endothelial cadherin and opens the paracellular pathway through fyn activation in human lung endothelia. Am J Physiol Lung Cell Mol Physiol (2006) 1.49
Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J Biol Chem (1999) 1.45
Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol (2012) 1.43
Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem (1993) 1.23
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J (2006) 1.12
Histamine stimulates phosphorylation of adherens junction proteins and alters their link to vimentin. Am J Physiol Lung Cell Mol Physiol (2002) 1.12
Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol (2012) 1.06
Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry (1991) 1.06
PtdIns(3,4,5)P3 gets its message across. Science (1997) 1.01
Casein kinase 2- and protein kinase A-regulated adenomatous polyposis coli and beta-catenin cellular localization is dependent on p38 MAPK. J Biol Chem (2005) 0.99
Beta-catenin regulates expression of cyclooxygenase-2 in articular chondrocytes. Biochem Biophys Res Commun (2002) 0.97
Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol (2008) 0.95
Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity. Biochem J (2003) 0.95
Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg (2000) 0.95
RhoA GTPase activation by TLR2 and TLR3 ligands: connecting via Src to NF-kappa B. J Immunol (2009) 0.94
Suppressing PTEN activity by tobacco smoke plus interleukin-1beta modulates dissociation of VE-cadherin/beta-catenin complexes in endothelium. Arterioscler Thromb Vasc Biol (2008) 0.92
Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem (2008) 0.91
Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest (1997) 0.90
The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem (2003) 0.87
The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. Biochemistry (1997) 0.82
Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. J Biol Chem (2004) 0.82
Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots. Biochem Cell Biol (2000) 0.81
Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2. J Lipid Res (1996) 0.78
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem (2003) 1.74
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol (2012) 1.55
Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem (2004) 1.21
Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis (2007) 1.18
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J (2006) 1.12
Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med (2006) 1.12
Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol (2012) 1.06
Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res (2013) 1.04
Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem (2006) 1.00
Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem (2003) 0.99
Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol (2003) 0.96
Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood (2007) 0.94
Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem (2008) 0.91
A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor. J Biol Chem (2002) 0.90
Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. J Lipid Res (2008) 0.89
High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis. Neoplasia (2012) 0.87
Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry (2006) 0.87
The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem (2003) 0.87
A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med (2002) 0.87
Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol (2008) 0.86
Role of the cofilin activity cycle in astrocytoma migration and invasion. Genes Cancer (2011) 0.85
Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly. J Biol Chem (2003) 0.83
Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance. Biochemistry (2004) 0.83
Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. J Biol Chem (2004) 0.82
Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3. Biochem J (2009) 0.82
The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis (2009) 0.82
Update on lipoprotein(a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep (2013) 0.81
Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10. Biochemistry (2005) 0.81
The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. Biochim Biophys Acta (2005) 0.80
Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J Biol Chem (2003) 0.80
Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J Lipid Res (2014) 0.80
Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation. Biochemistry (2004) 0.79
Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms. Int J Biochem Cell Biol (2013) 0.78
Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system. PLoS One (2013) 0.78
Nuclear magnetic resonance (NMR) solution structure, dynamics, and binding properties of the kringle IV type 8 module of apolipoprotein(a). Biochemistry (2007) 0.78
A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation. J Biol Chem (2003) 0.78
Plasminogen binds to plasmin-modulated factor Xa by Ca(2+) - and C-terminal lysine-dependent and -independent interactions. Thromb Haemost (2007) 0.78
Screening for and management of elevated Lp(a). Curr Cardiol Rep (2013) 0.77
Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit Dial Int (2002) 0.77
Overexpression of CD99 Increases the Migration and Invasiveness of Human Malignant Glioma Cells. Genes Cancer (2012) 0.77
Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone. Blood Coagul Fibrinolysis (2013) 0.76
Comparative analyses of the lysine binding site properties of apolipoprotein(a) kringle IV types 7 and 10. Biochemistry (2002) 0.75
Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter. Br J Haematol (2007) 0.75
A role for apolipoprotein(a) in protection of the low-density lipoprotein component of lipoprotein(a) from copper-mediated oxidation. Arch Biochem Biophys (2003) 0.75
An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler Thromb Vasc Biol (2005) 0.75
Activated protein C resistance and low molecular weight lipoprotein (a): dual pathogens for atherothrombosis? Thromb Res (2005) 0.75
Regulation of the mouse gene encoding TAFI by TNFα: role of NFκB binding site. Cytokine (2012) 0.75
Identification of a novel apolipoprotein(a)-related protein from the European hedgehog (Erinaceus europaeus). DNA Seq (2003) 0.75
The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity. Thromb Haemost (2013) 0.75